Quebec – Montreal – Saint-Laurent
Corporation
www.theratech.com
Quebec
Montreal
Saint-Laurent
Corporation
active
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers and develops innovative therapeutic products, with an emphasis on peptides, for commercialization. The Company targets unmet medical needs in specialty markets where it can retain all or part of the commercial rights to its products. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor. Tesamorelin will be exclusively commercialized in the U.S. by EMD Serono under the brand name EGRIFTAâ„¢. The Company's growth strategy is centered on the commercialization of EGRIFTAâ„¢ (tesamorelin for injection) in the United States through an agreement with EMD Serono, Inc. for the reduction of excess abdominal fat associated with lipodystrophy in HIV-infected patients. Moreover, Theratechnologies€™ growth strategy will also derive from the commercialization of EGRIFTAâ„¢ (tesamorelin for injection) in other markets for HIV-associated lipodystrophy, as well as the development of clinical programs for EGRIFTAâ„¢ (tesamorelin for injection) in other medical conditions.
Country of Ownership: Canada
Year Established: 1993
Exporting: No
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Services
Number of Employees: 98
Products:
Th9507, Thg213.29
Technology:
TH9507 is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date our studies suggest that TH9507 has several beneficial features: it reduces abdominal fat (in particular visceral fat), without compromising glycemic control (blood glucose), it increases muscle mass and improves the lipid profile. These characteristics make it an ideal candidate for the treatment of excess abdominal fat, an important aspect of HIV-associated lipodystrophy.
Sector:
Key / Major Clients: EGRIFTAâ„¢(tesamorelin for injection) was developed by Theratechnologies and will be exclusively commercialized in the U.S. by EMD Serono, Inc., an affiliate of Merck KGaA, of Darmstadt, Germany, under the terms of a collaboration and licensing agreement.
No associations
LandOfFree
Theratechnologies Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with Theratechnologies Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Theratechnologies Inc. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-15516